Intensive lowering of blOod pressure and low-density lipoprotein cholesterol with statin theraPy (LOBOCOP) may improve neointimal formation after coronary stenting in patients with coronary artery disease

Coronary Artery Disease

Volumn 20, Issue 4, 2009, Pages 288-294

  Takamiya, Yosuke ^a   Miura, Shin Ichiro ^a   Kawamura, Akira ^a   Tanigawa, Hiroyuki ^a   Zhang, Bo ^a   Iwata, Atsushi ^a   Nishikawa, Hiroaki ^a   Matsuo, Kunihiro ^a   Shirai, Kazuyuki ^a   Saku, Keijiro ^a  

^a FUKUOKA UNIVERSITY   (Japan)

Author keywords

Coronary artery disease; Intensive lowering therapy; Low density lipoprotein cholesterol; Neointimal formation; Statin

Indexed keywords

'TAXUS'; ACETYLSALICYLIC ACID; ADIPONECTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATORVASTATIN; CANDESARTAN; CLOPIDOGREL; CYPHER; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLMESARTAN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; TELMISARTAN; TICLOPIDINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANTIHYPERTENSIVE THERAPY; ARTERY INTIMA PROLIFERATION; ARTICLE; BARE METAL STENT; BLOOD PRESSURE REGULATION; BLOOD VESSEL DIAMETER; BODY MASS; CLINICAL ASSESSMENT; COMPARATIVE STUDY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; DIASTOLIC BLOOD PRESSURE; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; CHOLESTEROL, LDL; COMBINED MODALITY THERAPY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; DOWN-REGULATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERPLASIA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STENTS; TIME FACTORS; TREATMENT OUTCOME; TUNICA INTIMA;

EID: 67649644559     PISSN: 09546928     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCA.0b013e32832c4538     Document Type: Article

References (22)

1. Serruys PW, de Feyter P, Macaya C, Kokott N, Puel J, Vrolix M, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 287:3215-3222.
2. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007; 14:45-50.
3. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425-1435.
4. Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med 2005; 352:29-38.
5. Iwata A, Miura S, Shirai K, Kawamura A, Tomita S, Matsuo Y, et al. Lower level of low-density lipoprotein cholesterol by statin prevents progression of coronary restenosis after successful stenting in acute myocardial infarction. Intern Med 2006; 45:885-890.
6. Walter DH, Fichtlscherer S, Britten MB, Rosin P, Auch-Schwelk W, Schachinger V, Zeiher AM. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol 2001; 38:2006-2012.
7. Makuuchi H, Furuse A, Endo M, Nakamura H, Daida H, Watanabe M, et al. Effect of pravastatin on progression of coronary atherosclerosis in patients after coronary artery bypass surgery. Circ J 2005; 69:636-643.
8. Cruickshank J. The J-curve in hypertension. Curr Cardiol Rep 2003; 5:441-452.
9. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med 2003; 163:361-366.
10. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006; 144:884-893.
11. Saruta J. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Nippon Rinsho 2005; 63:952-958.
12. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349:1315-1323.
13. Fajadet J, Morice MC, Bode C, Barragan P, Serruys PW, Wijns W, et al. Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial. Circulation 2005; 111:1040-1044.
14. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004; 109:1942-1947.
15. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45:2088-2092.
16. Takeya M, Yoshimura T, Leonard EJ, Takahashi K. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol 1993; 24:534-539.
17. Furukawa Y, Matsumori A, Ohashi N, Shioi T, Ono K, Harada A, et al. Anti-monocyte chemoattractant protein-1 /monocyte chemotactic and activating factor antibody inhibits neointimal hyperplasia in injured rat carotid arteries. Circ Res 1999; 84:306-314.
18. Egashira K, Zhao Q, Kataoka C, Ohtani K, Usui M, Charo IF, et al. Importance of monocyte chemoattractant protein-1 pathway in neointimal hyperplasia after periarterial injury in mice and monkeys. Circ Res 2002; 90:1167-1172.
19. Sako H, Miura S, Iwata A, Nishikawa H, Kawamura A, Matsuo K, et al. Changes in CCR2 chemokine receptor expression and plasma MCP-1 concentration after the implantation of bare metal stents versus sirolimus-eluting stents in patients with stable angina Intern Med 2008; 47:7-13.
20. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol 2007; 2:1131 -1139.
21. Zhou MS, Jaimes EA, Raij L. Atorvastatin prevents end-organ injury in salt- sensitive hypertension: role of eNOS and oxidant stress. Hypertension 2004; 44:186-190.
22. Petronio AS, Amoroso G, Limbruno U, Papini B, De Carlo M, Micheli A, et al. Simvastatin does not inhibit intimal hyperplasia and restenosis but promotes plaque regression in normocholesterolemic patients undergoing coronary stenting: a randomized study with intravascular ultrasound. Am Heart J 2005; 149:520-526.